These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 3826754)

  • 21. Binding characteristics of KNI-272 to plasma proteins, a new potent tripeptide HIV protease inhibitor.
    Kiriyama A; Nishiura T; Ishino M; Yamamoto Y; Ogita I; Kiso Y; Takada K
    Biopharm Drug Dispos; 1996 Dec; 17(9):739-51. PubMed ID: 8968527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A simple method for the simulation of unbound serum disopyramide concentration in patients.
    Kishino S; Kohri N; Iseki K; Miyazaki K; Nomura A; Yasuda H
    J Pharmacobiodyn; 1991 Sep; 14(9):493-9. PubMed ID: 1779403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical pharmacokinetics of disopyramide.
    Siddoway LA; Woosley RL
    Clin Pharmacokinet; 1986; 11(3):214-22. PubMed ID: 3524956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The pharmacokinetics of disopyramide and mono-N-dealkyl-disopyramide in humans.
    Aitio ML; Allonen H; Kanto J; Mäntylä R
    Int J Clin Pharmacol Ther Toxicol; 1982 May; 20(5):219-26. PubMed ID: 7095921
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between alpha 1-acid glycoprotein and distribution of disopyramide and mono-N-dealkyldisopyramide in whole blood.
    Bredesen JE; Kierulf P
    Br J Clin Pharmacol; 1986 Sep; 22(3):281-6. PubMed ID: 3768240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum alpha 1-acid glycoprotein, sialic acid, and protein binding of disopyramide in normal subjects and cardiac patients.
    Chu JS; Kishion S; Nomura A; Miyazaki K
    Zhongguo Yao Li Xue Bao; 1997 Sep; 18(5):408-10. PubMed ID: 10322928
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of fluorescence immunoassay for total and unbound serum concentrations of disopyramide.
    Lima JJ; Shields BJ; Howell LH; MacKichan JJ
    Ther Drug Monit; 1984; 6(2):203-10. PubMed ID: 6377599
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic-pharmacodynamic analysis of unbound disopyramide directly measured in serial plasma samples in man.
    Thibonnier M; Holford NH; Upton RA; Blume CD; Williams RL
    J Pharmacokinet Biopharm; 1984 Dec; 12(6):559-73. PubMed ID: 6398364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protein binding of disopyramide and elevated alpha-1-acid glycoprotein concentrations in serum obtained from dialysis patients and renal transplant recipients.
    Haughey DB; Kraft CJ; Matzke GR; Keane WF; Halstenson CE
    Am J Nephrol; 1985; 5(1):35-9. PubMed ID: 3881959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of saturable binding to plasma proteins on the pharmacokinetic properties of disopyramide.
    Giacomini KM; Swezey SE; Turner-Tamiyasu K; Blaschke TF
    J Pharmacokinet Biopharm; 1982 Feb; 10(1):1-14. PubMed ID: 7069575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors influencing serum protein binding of lidocaine in humans.
    McNamara PJ; Slaughter RL; Pieper JA; Wyman MG; Lalka D
    Anesth Analg; 1981 Jun; 60(6):395-400. PubMed ID: 6165258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Applicability of capillary gas liquid chromatography to the measurement of free fraction of disopyramide in human plasma.
    Kapil RP; Axelson JE; Lalka D; Edwards DJ; Kerr CR
    Res Commun Chem Pathol Pharmacol; 1985 Apr; 48(1):153-6. PubMed ID: 3992030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pharmacodynamics and pharmacokinetics of disopyramide phosphate].
    Ol'binskaia LI; Tiukavkina NA; Kuz'mina MM; Beloborodov VL; Klimov AV
    Farmakol Toksikol; 1985; 48(4):73-8. PubMed ID: 3930285
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disopyramide. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias.
    Brogden RN; Todd PA
    Drugs; 1987 Aug; 34(2):151-87. PubMed ID: 3304965
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of concentration-dependent protein binding on serum concentrations and urinary excretion of disopyramide and its metabolite following oral administration.
    Haughey DB; Lima JJ
    Biopharm Drug Dispos; 1983; 4(2):103-12. PubMed ID: 6882879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determination of unbound fraction of disopyramide in plasma: a comparison of equilibrium dialysis, ultrafiltration through dialysis membranes and ultrafree anticonvulsant drug filters.
    Norris RL; Ahokas JT; Ravenscroft PJ
    J Pharmacol Methods; 1982 Jan; 7(1):7-14. PubMed ID: 7070107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The influence of protein binding on disopyramide clearance.
    Bryson SM; Lawrence JR; Steele WH; Campbell BC; Elliott HL; Sumner DJ
    Eur J Clin Pharmacol; 1982; 23(5):453-6. PubMed ID: 7151851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simultaneous determination of disopyramide and its mono-N-dealkylated metabolite enantiomers in human plasma and urine by enantioselective high-performance liquid chromatography.
    Takahashi H; Tamura A; Ogata H; Masuhara K
    J Chromatogr; 1990 Aug; 529(2):347-58. PubMed ID: 2229254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concentration-response relationships of disopyramide in patients with ventricular tachycardia.
    Duff HJ; Mitchell LB; Nath CF; Manyari DE; Baynton R; Wyse DG
    Clin Pharmacol Ther; 1989 May; 45(5):542-7. PubMed ID: 2721110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The influence of blood collection technique on serum and plasma protein binding of disopyramide.
    Haughey DB; Lima JJ
    Eur J Clin Pharmacol; 1982; 22(2):185-9. PubMed ID: 7094989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.